PAXBP1

Summary

PAXBP1 (PAX3 and PAX7 binding protein 1, HGNC:13579) is a protein-coding gene on chromosome 21q22.11, encoding PAX3- and PAX7-binding protein 1 (Q9Y5B6). Adapter protein linking the transcription factors PAX3 and PAX7 to the histone methylation machinery and involved in myogenesis. It is a common-essential gene (DepMap: required in 97.2% of cancer cell lines).

Predicted to enable DNA binding activity and histone methyltransferase binding activity. Predicted to be involved in positive regulation of transcription by RNA polymerase II. Predicted to act upstream of or within positive regulation of myoblast proliferation and regulation of skeletal muscle satellite cell proliferation. Located in cytosol.

Source: NCBI Gene 94104 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 131 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 97.2% of screened cell lines (common-essential)
• MANE Select transcript: NM_016631

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13579
Approved symbol	PAXBP1
Name	PAX3 and PAX7 binding protein 1
Location	21q22.11
Locus type	gene with protein product
Status	Approved
Aliases	GCFC, fSAP105
Ensembl gene	ENSG00000159086
Ensembl biotype	protein_coding
OMIM	617621
Entrez	94104

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 5 protein_coding, 3 nonsense_mediated_decay, 3 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000290178, ENST00000331923, ENST00000421049, ENST00000443785, ENST00000445049, ENST00000464256, ENST00000466846, ENST00000472588, ENST00000497873, ENST00000962012, ENST00000962013, ENST00000962014

RefSeq mRNA: 2 — MANE Select: NM_016631 NM_013329, NM_016631

CCDS: CCDS13619, CCDS33541

Canonical transcript exons

ENST00000331923 — 18 exons

Exon	Start	End
ENSE00001043135	32755230	32755353
ENSE00001418055	32771326	32771755
ENSE00001888460	32733899	32735067
ENSE00003475039	32762096	32762317
ENSE00003479846	32751119	32751218
ENSE00003485802	32738173	32738319
ENSE00003491166	32743678	32743754
ENSE00003514300	32748499	32748698
ENSE00003531041	32745574	32745718
ENSE00003564031	32744792	32744913
ENSE00003576082	32759777	32759994
ENSE00003586691	32769814	32769942
ENSE00003600861	32759080	32759269
ENSE00003613165	32743248	32743314
ENSE00003619321	32761059	32761162
ENSE00003659463	32750917	32751032
ENSE00003689070	32764348	32764524
ENSE00003693611	32737254	32737408

Expression profiles

Bgee: expression breadth ubiquitous, 289 present calls, max score 96.98.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 31.3487 / max 803.2397, expressed in 1812 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
190210	25.6274	1802
190211	3.0017	1063
190209	1.2235	642
190212	1.0946	520
190208	0.2339	65
190213	0.1676	85

Top tissues by expression

292 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	96.98	gold quality
sperm	CL:0000019	95.12	gold quality
right uterine tube	UBERON:0001302	94.47	gold quality
left ovary	UBERON:0002119	94.30	gold quality
calcaneal tendon	UBERON:0003701	93.99	gold quality
tibia	UBERON:0000979	93.85	gold quality
right ovary	UBERON:0002118	93.84	gold quality
male germ cell	CL:0000015	93.15	gold quality
ventricular zone	UBERON:0003053	93.04	gold quality
corpus callosum	UBERON:0002336	92.76	gold quality
right hemisphere of cerebellum	UBERON:0014890	92.52	gold quality
cerebellar hemisphere	UBERON:0002245	92.45	gold quality
ovary	UBERON:0000992	92.41	gold quality
cerebellar cortex	UBERON:0002129	92.31	gold quality
jejunal mucosa	UBERON:0000399	92.28	gold quality
tibial nerve	UBERON:0001323	92.23	gold quality
ganglionic eminence	UBERON:0004023	92.12	gold quality
germinal epithelium of ovary	UBERON:0001304	91.85	gold quality
cerebellum	UBERON:0002037	91.72	gold quality
embryo	UBERON:0000922	91.39	gold quality
body of pancreas	UBERON:0001150	91.26	gold quality
small intestine Peyer’s patch	UBERON:0003454	91.24	gold quality
adenohypophysis	UBERON:0002196	91.21	gold quality
body of uterus	UBERON:0009853	91.18	gold quality
visceral pleura	UBERON:0002401	91.12	gold quality
endocervix	UBERON:0000458	91.06	gold quality
duodenum	UBERON:0002114	90.94	gold quality
muscle layer of sigmoid colon	UBERON:0035805	90.93	gold quality
pleura	UBERON:0000977	90.91	gold quality
adrenal tissue	UBERON:0018303	90.80	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.53

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

22 targeting PAXBP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-379-3P	99.69	69.60	1524
HSA-MIR-411-3P	99.69	69.63	1524
HSA-MIR-3618	99.69	68.57	1012
HSA-MIR-4328	99.57	71.06	4094
HSA-MIR-186-3P	99.51	66.24	1685
HSA-MIR-4426	99.17	66.74	1949
HSA-MIR-7151-3P	99.04	69.72	2370
HSA-MIR-934	98.49	70.44	581
HSA-MIR-4662B	98.33	66.37	1163
HSA-MIR-4647	98.30	66.41	1139
HSA-MIR-4768-3P	98.16	66.02	2330
HSA-MIR-4638-3P	97.90	65.75	905
HSA-MIR-3667-5P	97.16	64.87	591

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 97.2% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 2)

• The GCFC1/C21orf66 distal promoter contains an inhibitory cis-regulatory element that is responsive to Trichostatin A (TSA) treatment according to promoter reporter assays in HEK 293 cells. (PMID:20494980)
• A homozygous potentially pathogenic variant in the PAXBP1 gene in a large family with global developmental delay and myopathic hypotonia has been reported. (PMID:28542722)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	paxbp1	ENSDARG00000062361
mus_musculus	Paxbp1	ENSMUSG00000022974
rattus_norvegicus	Paxbp1	ENSRNOG00000002036
drosophila_melanogaster	CG1965	FBGN0037466
caenorhabditis_elegans	mog-7	WBGENE00009672

Paralogs (1): GCFC2 (ENSG00000005436)

Protein

Protein identifiers

PAX3- and PAX7-binding protein 1 — Q9Y5B6 (reviewed: Q9Y5B6)

Alternative names: GC-rich sequence DNA-binding factor 1

All UniProt accessions (3): Q9Y5B6, H7BZC8, H7C2W4

UniProt curated annotations — full annotation on UniProt →

Function. Adapter protein linking the transcription factors PAX3 and PAX7 to the histone methylation machinery and involved in myogenesis. Associates with a histone methyltransferase complex that specifically mediates dimethylation and trimethylation of ‘Lys-4’ of histone H3. Mediates the recruitment of that complex to the transcription factors PAX3 and PAX7 on chromatin to regulate the expression of genes involved in muscle progenitor cells proliferation including ID3 and CDC20.

Subunit / interactions. Interacts with PAX3 and PAX7. Interacts with WDR5; associates with a histone methyltransferase (HMT) complex composed at least of RBBP5, ASH2L, SET1, SET2 and KMT2A/MLL1, KMT2D/MLL2, KMT2C/MLL3 and KMT2B/MLL4 through direct interaction with WDR5.

Subcellular location. Nucleus.

Tissue specificity. Ubiquitous.

Miscellaneous. Most abundantly expressed isoform, at mRNA level according to PubMed:11707072, despite the presence of a premature stop codon in the mRNA that may lead to nonsense-mediated mRNA decay.

Similarity. Belongs to the GCF family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q9Y5B6-1	1, A	yes
Q9Y5B6-2	2, B
Q9Y5B6-3	3, C
Q9Y5B6-4	4, D

RefSeq proteins (2): NP_037461, NP_057715* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR012890	GCFC2-like	Family
IPR022783	GCFC_dom	Domain

Pfam: PF07842

UniProt features (35 total): modified residue 10, compositionally biased region 9, region of interest 6, splice variant 5, cross-link 2, chain 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
8RO2	ELECTRON MICROSCOPY	3.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y5B6-F1	72.59	0.40

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (12): 16, 154, 155, 158, 191, 262, 295, 557, 558, 563, 149, 149

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 262 (showing top): GOBP_MUSCLE_CELL_PROLIFERATION, GOBP_MUSCLE_STRUCTURE_DEVELOPMENT, GOBP_RNA_SPLICING, PYEON_CANCER_HEAD_AND_NECK_VS_CERVICAL_UP, DODD_NASOPHARYNGEAL_CARCINOMA_UP, BROWN_MYELOID_CELL_DEVELOPMENT_DN, GOBP_STRIATED_MUSCLE_CELL_PROLIFERATION, BASAKI_YBX1_TARGETS_DN, ZHANG_BREAST_CANCER_PROGENITORS_UP, MODULE_207, GTGACTT_MIR224, chr21q22, BURTON_ADIPOGENESIS_11, PARENT_MTOR_SIGNALING_DN, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_2

GO Biological Process (6): mRNA splicing, via spliceosome (GO:0000398), transcription by RNA polymerase II (GO:0006366), muscle organ development (GO:0007517), regulation of skeletal muscle satellite cell proliferation (GO:0014842), positive regulation of transcription by RNA polymerase II (GO:0045944), positive regulation of myoblast proliferation (GO:2000288)

GO Molecular Function (2): DNA binding (GO:0003677), histone methyltransferase binding (GO:1990226)

GO Cellular Component (2): nucleus (GO:0005634), cytosol (GO:0005829)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	1
mRNA processing	1
DNA-templated transcription	1
animal organ development	1
muscle structure development	1
skeletal muscle satellite cell proliferation	1
regulation of skeletal muscle cell proliferation	1
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
positive regulation of DNA-templated transcription	1
positive regulation of cell population proliferation	1
myoblast proliferation	1
regulation of myoblast proliferation	1
nucleic acid binding	1
enzyme binding	1
intracellular membrane-bounded organelle	1
cytoplasm	1
cellular anatomical structure	1

Protein interactions and networks

STRING

968 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PAXBP1	SYNJ1	O43426	550
PAXBP1	MAP6D1	Q9H9H5	501
PAXBP1	PAX3	P23760	499
PAXBP1	TMEM50B	P56557	492
PAXBP1	COMTD1	Q86VU5	489
PAXBP1	TBATA	Q96M53	485
PAXBP1	DISP2	A7MBM2	479
PAXBP1	DUS2	Q9NX74	473
PAXBP1	EVA1C	P58658	471
PAXBP1	IL10RB	Q08334	464
PAXBP1	DOP1B	Q9Y3R5	463
PAXBP1	TMC4	Q7Z404	461
PAXBP1	COPRS	Q9NQ92	460
PAXBP1	GET1	O00258	442
PAXBP1	CAMK1G	Q96NX5	440

IntAct

87 interactions, top by confidence:

A	B	Type	Score
LSM3	LSM1	psi-mi:“MI:0914”(association)	0.950
SNRNP40	SNRNP200	psi-mi:“MI:0914”(association)	0.810
SNRPE	GEMIN2	psi-mi:“MI:0914”(association)	0.770
SNRPG	GEMIN2	psi-mi:“MI:0914”(association)	0.710
SNRPB	PRMT5	psi-mi:“MI:0914”(association)	0.670
HDAC11	CLUH	psi-mi:“MI:0914”(association)	0.640
SF3B1	SAP18	psi-mi:“MI:0914”(association)	0.640
DDX23	PRPF4	psi-mi:“MI:0914”(association)	0.640
SNRPA1	U2SURP	psi-mi:“MI:0914”(association)	0.640
TFIP11	DHX15	psi-mi:“MI:0914”(association)	0.600
RSRC1	JMJD6	psi-mi:“MI:0914”(association)	0.550
SNRPE	PRMT5	psi-mi:“MI:0914”(association)	0.530
SNRPN	PRMT5	psi-mi:“MI:0914”(association)	0.530
KIAA1143	AQR	psi-mi:“MI:0914”(association)	0.530
JPH4	ZSWIM8	psi-mi:“MI:0914”(association)	0.530
SNRPE	SNRPGP15	psi-mi:“MI:0914”(association)	0.530
SNRPF	SNRPGP15	psi-mi:“MI:0914”(association)	0.530
SRPK2	RRP9	psi-mi:“MI:0914”(association)	0.530
EFTUD2	AQR	psi-mi:“MI:0914”(association)	0.530
SNRNP40	AQR	psi-mi:“MI:0914”(association)	0.530
steC	SCD	psi-mi:“MI:0914”(association)	0.460
Prpf8		psi-mi:“MI:0915”(physical association)	0.400
Snw1	DHX15	psi-mi:“MI:0915”(physical association)	0.400
JUN		psi-mi:“MI:0914”(association)	0.350
MKI67	ARHGAP10	psi-mi:“MI:0914”(association)	0.350
ESR1	ESYT2	psi-mi:“MI:0914”(association)	0.350

BioGRID (154): PAXBP1 (Affinity Capture-RNA), PAXBP1 (Affinity Capture-RNA), PAXBP1 (Affinity Capture-MS), PAXBP1 (Affinity Capture-MS), PAXBP1 (Affinity Capture-MS), PAXBP1 (Affinity Capture-MS), PAXBP1 (Affinity Capture-MS), PAXBP1 (Co-fractionation), PAXBP1 (Proximity Label-MS), PAXBP1 (Affinity Capture-MS), PAXBP1 (Affinity Capture-MS), PAXBP1 (Affinity Capture-MS), PAXBP1 (Affinity Capture-MS), PAXBP1 (Affinity Capture-MS), PAXBP1 (Affinity Capture-MS)

ESM2 similar proteins: A2BDB7, A2CE83, B2ZX90, D3IUT5, E1BXS0, F4IDY7, P0DPK0, P49069, P58501, Q07532, Q0P4A6, Q1JQE2, Q28GJ0, Q28GL6, Q2KJD6, Q2MJV9, Q2TBJ0, Q2WG79, Q2WG80, Q5F3D1, Q5R789, Q5TID7, Q5U3I2, Q5ZHQ6, Q640U0, Q641E3, Q66H73, Q67W65, Q68F53, Q6AYN9, Q6DRL4, Q6NZY4, Q7TPE5, Q7Z2Z1, Q7ZX27, Q80YR7, Q80ZU5, Q86XK3, Q8BQ33, Q8C6C7

Diamond homologs: P16383, P58501, Q8BKT3, Q9Y5B6

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 102 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Metabolism of non-coding RNA	6	53.6×	3e-08
mRNA Splicing - Minor Pathway	12	37.9×	1e-14
mRNA Splicing	21	32.5×	9e-25
RNA Polymerase II Transcription Termination	9	27.8×	1e-09
Processing of Capped Intron-Containing Pre-mRNA	22	25.5×	1e-23
mRNA Splicing - Major Pathway	33	25.4×	2e-36
SARS-CoV-2 modulates host translation machinery	8	25.2×	3e-08
mRNA Polyadenylation	19	23.5×	1e-19

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of mRNA splicing, via spliceosome	7	60.2×	2e-09
spliceosomal snRNP assembly	9	58.8×	4e-12
RNA splicing, via transesterification reactions	8	56.1×	1e-10
U2-type prespliceosome assembly	8	56.1×	1e-10
spliceosomal complex assembly	6	40.6×	5e-07
mRNA splicing, via spliceosome	27	27.8×	3e-29
RNA splicing	23	22.8×	9e-23
RNA processing	7	17.2×	1e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

131 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	98
Likely benign	8
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

2532 predictions. Top by Δscore:

Variant	Effect	Δscore
21:32735067:CCT:C	acceptor_loss	1.0000
21:32735068:CTA:C	acceptor_loss	1.0000
21:32737249:ATTAC:A	donor_loss	1.0000
21:32737250:TTA:T	donor_loss	1.0000
21:32737252:ACC:A	donor_loss	1.0000
21:32737253:C:A	donor_loss	1.0000
21:32737405:TTAC:T	acceptor_gain	1.0000
21:32737406:TACC:T	acceptor_loss	1.0000
21:32737407:ACCT:A	acceptor_loss	1.0000
21:32737408:CCT:C	acceptor_loss	1.0000
21:32737409:C:CC	acceptor_gain	1.0000
21:32737409:CTGTG:C	acceptor_loss	1.0000
21:32737410:T:G	acceptor_loss	1.0000
21:32738167:A:C	donor_gain	1.0000
21:32738168:CTCAC:C	donor_loss	1.0000
21:32738171:A:AC	donor_gain	1.0000
21:32738172:C:CC	donor_gain	1.0000
21:32738172:C:CT	donor_loss	1.0000
21:32738172:CATT:C	donor_gain	1.0000
21:32738317:CAG:C	acceptor_gain	1.0000
21:32741504:A:AC	donor_gain	1.0000
21:32741505:C:CC	donor_gain	1.0000
21:32741526:AAGG:A	donor_gain	1.0000
21:32743676:A:AC	donor_gain	1.0000
21:32743677:C:CC	donor_gain	1.0000
21:32744914:C:CC	acceptor_gain	1.0000
21:32745664:C:CT	acceptor_gain	1.0000
21:32745665:A:C	acceptor_gain	1.0000
21:32745714:TTTGC:T	acceptor_gain	1.0000
21:32745715:TTGC:T	acceptor_gain	1.0000

AlphaMissense

6039 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
21:32738237:C:G	R806P	1.000
21:32743270:C:G	R771P	1.000
21:32744896:A:G	W696R	1.000
21:32744896:A:T	W696R	1.000
21:32745688:A:G	W652R	1.000
21:32745688:A:T	W652R	1.000
21:32748609:A:G	W605R	1.000
21:32748609:A:T	W605R	1.000
21:32750965:C:G	D559H	1.000
21:32750966:A:C	S558R	1.000
21:32750966:A:T	S558R	1.000
21:32750968:T:G	S558R	1.000
21:32750977:C:G	G555R	1.000
21:32751011:T:A	R543S	1.000
21:32751011:T:G	R543S	1.000
21:32751012:C:G	R543T	1.000
21:32751024:C:G	R539P	1.000
21:32751025:G:T	R539S	1.000
21:32751027:C:G	R538P	1.000
21:32751032:C:A	R536S	1.000
21:32751032:C:G	R536S	1.000
21:32751119:C:A	R536M	1.000
21:32751119:C:G	R536T	1.000
21:32751121:C:A	R535S	1.000
21:32751121:C:G	R535S	1.000
21:32751122:C:A	R535M	1.000
21:32751122:C:G	R535T	1.000
21:32751126:C:G	A534P	1.000
21:32751131:C:G	R532P	1.000
21:32751144:G:T	R528S	1.000

dbSNP variants (sampled 300 via entrez): RS1000030411 (21:32753086 A>C), RS1000098758 (21:32773713 A>G), RS1000146210 (21:32752894 G>A,C,T), RS1000228634 (21:32759591 G>A,T), RS1000317533 (21:32761539 T>C), RS1000350212 (21:32766346 T>A,C), RS1000366071 (21:32734430 G>A,T), RS1000371663 (21:32761754 G>A), RS1000462200 (21:32772133 TCAGA>T), RS1000528448 (21:32748278 AAAC>A,AAACAAC), RS1000645752 (21:32771826 A>T), RS1000696363 (21:32741143 C>T), RS1000706878 (21:32746508 A>C), RS1000802342 (21:32761280 G>T), RS1000835890 (21:32740202 A>G)

Disease associations

OMIM: gene MIM:617621 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5725180 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.44	Kd	36	nM	MOLIBRESIB
7.22	IC50	60	nM	MOLIBRESIB

PubChem BioAssay actives

2 with measured affinity, of 7 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2179132: Binding affinity against C21ORF66 (unknown origin) assessed as apparent dissociation constant incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	kd	0.0360	uM

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression	2
GSK-J4	increases expression	1
FR900359	increases phosphorylation	1
TAK-243	decreases sumoylation	1
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
beta-lapachone	increases expression	1
methylparaben	increases expression	1
sodium arsenite	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
Sunitinib	increases expression	1
Acetaldehyde	increases expression	1
Acetaminophen	increases expression	1
Benzene	increases expression	1
Caffeine	affects phosphorylation	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Doxorubicin	decreases expression	1
Formaldehyde	decreases expression	1
Ivermectin	decreases expression	1
Lead	affects expression	1
Methylcholanthrene	affects binding, increases reaction	1
Selenium	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Vitamin E	decreases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	1
Tungsten Compounds	increases expression	1
Sodium Selenite	decreases expression	1
Antirheumatic Agents	increases expression	1
Cadmium Chloride	decreases expression	1

ChEMBL screening assays

7 unique, capped per target: 7 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5697188	Binding	Inhibition of C21ORF66 (unknown origin) assessed as fold change at 10 uM incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. — Nature

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.